# Adrian Kielhorn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/adrian-kielhorn/

## Facts

| Field | Value |
| --- | --- |
| Citations | 862 |
| Field | Multiple Sclerosis Research Studies |
| h-index | 16 |
| i10-index | 20 |
| Last Known Institution | AstraZeneca (Brazil) |
| OpenAlex ID | https://openalex.org/A5029091154 |
| Works | 111 |

## Researcher papers

- [Economic burden of hospitalizations of Medicare beneficiaries with heart failure](https://scholariq.org/papers/economic-burden-of-hospitalizations-of-medicare-beneficiaries-with-heart-failure/)
- [Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs](https://scholariq.org/papers/indirect-comparison-of-tocilizumab-and-other-biologic-agents-in-patients-with/)
- [UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug](https://scholariq.org/papers/uk-cost-utility-analysis-of-rituximab-in-patients-with-rheumatoid-arthritis-that/)
- [Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice](https://scholariq.org/papers/neuromyelitis-optica-spectrum-disorder-clinical-burden-and-cost-of-relapses-and/)
- [Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe](https://scholariq.org/papers/retrospective-cost-analysis-of-gemcitabine-in-combination-with-cisplatin-in-non/)
- [Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center](https://scholariq.org/papers/pharmacotherapy-treatment-patterns-outcomes-and-health-resource-utilization/)
- [Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure](https://scholariq.org/papers/cost-effectiveness-analysis-of-rituximab-treatment-in-patients-in-germany-with/)
- [Cost‐Effectiveness of Ivabradine for Heart Failure in the United States](https://scholariq.org/papers/cost-effectiveness-of-ivabradine-for-heart-failure-in-the-united-states/)
- [Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder](https://scholariq.org/papers/network-meta-analysis-of-food-and-drug-administration-approved-treatment-options/)
- [Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group a streptococcal tonsillopharyngitis in children](https://scholariq.org/papers/five-days-of-erythromycin-estolate-versus-ten-days-of-penicillin-v-in-the/)
- [PND31 AMYOTROPHIC LATERAL SCLEROSIS (ALS) RESULTS IN HIGH DIRECT AND INDIRECT COSTS TO PATIENTS, CAREGIVERS, AND HEALTHCARE SYSTEMS](https://scholariq.org/papers/pnd31-amyotrophic-lateral-sclerosis-als-results-in-high-direct-and-indirect/)

## Researcher topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

## Researcher university

- [AstraZeneca (Brazil)](https://scholariq.org/institutions/astrazeneca-brazil/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.